To Increase Patient Access
End Brain Cancer Mobile App to download your number one tool for navigating this disease.

June 28, 2024

Pediatric Clinical Trial for DIPG Brain Cancer

sonalasense logo

SonALAsense is currently recruiting patients in a Phase 2 Study of Sonodynamic Therapy using SONALA-001 and Exablate 4000 Type 2.0 in patients With Diffuse Intrinsic Pontine Glioma (DIPG).

brain scan illustration

SonALAsense presented preliminary data from the clinical study in late 2023. Initial clinical activity observed in the first 5 patients showed partial responses of at least 25% reduction in tumor size in 2 (40%) patients through eight weeks post treatment and stable disease in 2 (40%) patients. Four patients treated have exceeded the median survival of 9-11 months post diagnosis. Patients treated have also maintained or improved their patient performance status.

“We are pleased with the early results and the safety profile of SONALA-001 SDT,” said Hasan R. Syed, M.D., pediatric neurosurgeon at Children’s National Hospital and co-lead in Principal Investigator Roger Packer’s trial. “Sonodynamic therapy is part of a larger trend towards less invasive treatment paradigms in neurosurgery. For families of children with DIPG, this trial offers hope and a chance to potentially alter the course of this aggressive disease.”

Actively Recruiting Sites

  • San Francisco, CA - University of California
  • Washington DC - Children's National / Children's Research Institute
  • Miami, FL - Nicklaus Children's Hospital

For more information on inclusion/exclusion criteria and active sites, click the button below and fill out the Interest Form. The End Brain Cancer Initiative's Clinical Research Coordinator/Patient Navigator will contact you to help you figure out if this study may be a good fit, and if so, will “DIRECTLY CONNECT” you to the site and specialist closest to where you live.

Shreya Prakash photo

Contact Shreya Prakash

Clinical Research Coordinator
& Patient Navigator

contact QR code

EBCI app on cell phone


Scan or click the QR code to download the App now!


Enhancing patient outcomes by expanding FDA-approved treatment modalities and fueling research in the pharma/bio/life sciences, device & diagnostic industries and by closing the existing GAP from initial diagnosis to IMMEDIATE AND EXPANDED ACCESS to specialists, researchers, advanced & innovative treatments, clinical trials and critical care with the ultimate goal of improving patient outcomes through updating and improving WHO & NCCN Guidelines and clinical practices related to Standard of Care for brain cancer patients.

TAX ID:26-2185614
corporate partners
upcoming events
About us
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram